Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis.
Kevin R BaineyGuillaume Marquis-GravelBlair J MacDonaldDavid BewickAndrew YanRicky D TurgeonPublished in: PloS one (2023)
In HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- atrial fibrillation
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- brain injury
- patient reported
- blood brain barrier
- subarachnoid hemorrhage
- breast cancer risk